Søren Johan Brun
Copenhagen, December 2021
“ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its capsid virus-like particle (cVLP) breast cancer vaccine candidate ES2B-C001 demonstrated strong tumor-growth inhibiting effect in a mice model, thus reaching an important pre-clinical milestone ahead of schedule.”
Read more about the exciting news HERE.
Expres2ion was Gemstone Capital’s first IPO (2016)
